Mesothelioma Treatment: Radiation Or Radiotherapy
By KhmengWat.com
Mesothelioma is a cancerous disease that affects the serous linings of various internal organs in the human body. Among them, the lungs, heart and the stomach are the mostly affected.It is Read more...
|
|
Expression of a splice variant of cxcr3 in crohn's disease patients; indication for a lymphocyte—epithelial cell interaction
Background and Aim: T-lymphocyte migration is implicated in the pathogenesis of Crohn's disease (CD) and ulcerative colitis (UC). CXC chemokines MIG, IP-10, and I-TAC act by binding to CXCR3 receptor on T-lymphocytes. We investigated the role of these chemokines and their receptor in patients with UC, CD, and normal controls (NC).Methods: Chemokine expression and serum levels were examined in colonic biopsies from patients and NC using reverse transcription[ndash]polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay. HT-29 and Caco2 colonic epithelial cells were studied following in vitro stimulation with proinflammatory (Th1) and Th2-derived cytokines. CXCR3 receptor expression was assessed in CD3+ peripheral blood lymphocytes (PBL) from patients and NC and in stimulated Jurkat leukaemia cells, using RT-PCR and flow cytometry.Results: Full size CXCR3 mRNA (FS) expression was found in CD3+ PBL from controls and UC, but not from CD patients. In contrast, CD3+ PBL from CD patients showed a marked mRNA expression of the spliced variant CXCR3 (TV). This finding explains the high expression of CXCR3 on CD3+ PBL from CD patients in flow cytometry. Increased chemokine expression and production was found in colonic biopsies and serum from CD compared to UC patients and controls. Stimulation of epithelial cells with proinflammatory cytokines significantly induced chemokine production. The addition of Th2 cytokines had an inhibitory effect. Stimulation of Jurkat cells with cytokines and supernatant conditioned media from epithelial cells induced CXCR3TV expression.Conclusions: These data demonstrate that PBL from CD patients express a spliced variant of the CXCR3 receptor and suggest a role for the colonic epithelial cells in T-lymphocyte migration in intestinal inflammation. (Source: Journal of Gastroenterology and Hepatology) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Current application of confocal endomicroscopy in gastrointestinal disorders
Confocal endomicroscopy (CEM) is a recent advancement in imaging technology that incorporates a confocal laser microscope into the tip of a flexible endoscope. The 1000-fold magnification and high resolution allows for real time in vivo histology or "virtual biopsies" of the gastrointestinal tract mucosa. CEM has the capability to instantaneously diagnose intra-epithelial neoplasia during endoscopy, alone or in combination with a "red-flag" technique, such as chromoendoscopy. Therefore, there is clinical utility in the surveillance or diagnosis of Barrett's esophagus, gastric intestinal metaplasia and cancer, longstanding ulcerative colitis, and colonic neoplasia. Furthermore, CEM also appears to be useful in the evaluation of coeliac disease, microscopic colitis, and in diagnosing Helicobacter pylori chronic gastritis. This review examines the current available data on the utility of this new technology in clinical gastroenterology and its potential impact in the future. (Source: Journal of Gastroenterology and Hepatology)
Response to letter by field et al, "influenza vaccinations: should they really be encouraged for ibd patients being treated with immunosuppressives?"
No abstract. (Source: Inflammatory Bowel Diseases)
Oral crohn's disease: a favorable clinical response with delayed-release triamcinolone acetonide intralesional injections
(Source: The American Journal of Gastroenterology)
Toll-like receptor-4 signaling: a possible candidate pathway to support tobacco smoking effects in ulcerative colitis
(Source: The American Journal of Gastroenterology)
Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis
(Source: The American Journal of Gastroenterology) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Stem cell treatment hope for inflammatory bowel disease patients
Bone marrow stem cells could provide a new and effective treatment for patients with inflammatory bowel disease, results of a study in mice suggest. (Source: MedWire News - Consumer Health)
Biologic therapy for crohn's disease: clinical experience in patients who have had previous anti-tnf treatment
Remo Panaccione, MD, FRCP, explores the issues and available evidence in regard to the management of Crohn's disease patients with prior anti-TNF experience.
Medscape Gastroenterology (Source: Medscape FamilyMedicine Headlines)
Original contribution: nut, corn, and popcorn consumption and the incidence of diverticular disease
Context Patients with diverticular disease are frequently advised to avoid eating nuts, corn, popcorn, and seeds to reduce the risk of complications. However, there is little evidence to support this recommendation.
Objective To determine whether nut, corn, or popcorn consumption is associated with diverticulitis and diverticular bleeding.
Design and Setting The Health Professionals Follow-up Study is a cohort of US men followed up prospectively from 1986 to 2004 via self-administered questionnaires about medical (biennial) and dietary (every 4 years) information. Men reporting newly diagnosed diverticulosis or diverticulitis were mailed supplemental questionnaires.
Participants The study included 47 228 men aged 40 to 75 years who at baseline were free of diverticulosis or its complications, cancer, and inflammatory bowel disease and returned a food-frequency questionnaire.
Main Outcome Measures Incident diverticulitis and diverticular bleeding.
Results During 18 years of follow-up, there were 801 incident cases of diverticulitis and 383 incident cases of diverticular bleeding. We found inverse associations between nut and popcorn consumption and the risk of diverticulitis. The multivariate hazard ratios for men with the highest intake of each food (at least twice per week) compared with men with the lowest intake (less than once per month) were 0.80 (95% confidence interval, 0.63-1.01; P for trend = .04) for nuts and 0.72 (95% confidence interval, 0.56-0.92; P for trend = .007) for popcorn. No associations were seen between corn consumption and diverticulitis or between nut, corn, or popcorn consumption and diverticular bleeding or uncomplicated diverticulosis.
Conclusions In this large, prospective study of men without known diverticular disease, nut, corn, and popcorn consumption did not increase the risk of diverticulosis or diverticular complications. The recommendation to avoid these foods to prevent diverticular complications should be reconsidered. (Source: JAMA)
Azathioprine is effective for the treatment of both crohn's disease (cd) and ulcerative colitis
(Source: Inpharma)
Influence of genotyping error in linkage mapping for complex traits - an analytic study
Background:
Despite the current trend towards large epidemiological studies of unrelated individuals, linkage studies in families are still thoroughly being utilized as tools for disease gene mapping. The use of the single-nucleotide-polymorphisms (SNP) array technology in genotyping of family data has the potential to provide more informative linkage data. Nevertheless, SNP array data are not immune to genotyping error which, as has been suggested in the past, could dramatically affect the evidence for linkage especially in selective designs such as affected sib pair (ASP) designs. The influence of genotyping error on selective designs for continuous traits has not been assessed yet.
Results:
We use the identity-by-descent (IBD) regression-based paradigm for linkage testing to analytically quantify the effect of simple genotyping error models under specific selection schemes for sibling pairs. We show, for example, that in extremely concordant (EC) designs, genotyping error leads to decreased power whereas it leads to increased type I error in extremely discordant (ED) designs. Perhaps surprisingly, the effect of genotyping error on inference is most severe in designs where selection is least extreme. We suggest a genomic control for genotyping errors via a simple modification of the intercept in the regression for linkage.
Conclusions:
This study extends earlier findings: genotyping error can substantially affect type I error and power in selective designs for continuous traits. Designs involving both EC and ED sib pairs are fairly immune to genotyping error. When those designs are not feasible the simple genomic control strategy that we suggest offers the potential to deliver more robust inference, especially if genotyping is carried out by SNP array technology. (Source: BioMed Central) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
New study shows health benefits of probiotic could extend beyond gastrointestinal system
August 25, 2008 (Newswise) - Data from a recent study demonstrate the anti-inflammatory and pathogen protection benefits of Bifidobacterium infantis 35624 a probiotic bacterial strain of human origin. Gastrointestinal benefits of probiotics have been well-documented, but more and more research is revealing that probiotic benefits extend to the entire body. The report was published in the August issue of the Public Library of Science (PLoS) Pathogens .
The inflammatory response is a key part of the immune system?s battle against invaders. The normal response to infection is rapid and effective, however, the immune response may occasionally cause inflammation and damage to healthy tissue.
?Inflammation is a major factor in a number of chronic diseases affecting millions of people and can cause an unwanted impact on healthy tissue,? said Dr. Liam O?Mahony, lead investigator. ?Past research has shown that the probiotic Bifidobacterium infantis 35624 can positively impact the body?s immune defense3, and this most recent data suggests that its benefits are not restricted to the gastrointestinal tract.?
Inflammation is associated with a wide range of conditions, such as inflammatory bowel disease, arthritis, bacterial-induced colitis, type I diabetes and organ transplantation. Bifidobacterium infantis 35624 has previously shown ability to modulate the inflammatory response in a clinical trial of patients with irritable bowel syndrome.2 The new data suggests additional health benefits of this particular probiotic strain.
The published study examined the effect of Bifidobacterium infantis 35624 administration on immunity to Salmonella (Salmonella typhimurium), harmful bacteria that can cause intestinal infections and trigger the body?s inflammatory response. Bifidobacterium infantis 35624, a probiotic strain isolated from healthy human gastrointestinal tissue, was administered to mice in freeze-dried powder at least three weeks prior to salmonella infection. Animals that received Bifidobacterium infantis 35624 showed dramatically increased numbers of certain immune cells that control the immune system response to harmful pathogens, in this case Salmonella.
Additionally, data show increased numbers of T-regulatory (Treg) cells, or cells that suppress inflammatory disease in a wide range of autoimmune diseases. Administration of Bifidobacterium infantis 35624 resulted in the induction of these Treg cells, which protected the host from excessive inflammation during the course of infection. Researchers concluded that the introduction of Bifidobacterium infantis 35624 results in enhanced protection from infection, while limiting pro-inflammatory damage caused by superfluous activation of the innate immune system.
About Alimentary Health
Alimentary Health is a development stage specialty biotechnology company located in Ireland. The company is focused on the discovery, development and commercialization of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. Alimentary Health is the foundation industry partner of the Alimentary Pharmabiotic Center based at University College Cork, Ireland. www.alimentaryhealth.ie (Source: Diabetes News from dLife.com)
Grey-scale and colour doppler sonography in the evaluation of children with suspected bowel inflammation: correlation with colonoscopy and histological findings.
<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Display&dopt=PubMed_PubMed&from_uid=18718226">Related Articles</a></td></tr></table>
<p><b>Grey-scale and colour Doppler sonography in the evaluation of children with suspected bowel inflammation: correlation with colonoscopy and histological findings.</b></p>
<p>Clin Radiol. 2008 Sep;63(9):968-78</p>
<p>Authors: Epifanio M, Baldisserotto M, Spolidoro JV, Gaiger A</p>
<p>AIM: To evaluate the correlation of grey-scale and colour Doppler sonography with colonoscopy and histology to detect bowel inflammation in children. MATERIAL AND METHODS: The records of 72 patients with suspected bowel inflammation were reviewed retrospectively. Patients were included in the study if sonography had been performed up to 30 days before colonoscopy. Grey-scale and colour Doppler sonography were used to evaluate bowel wall thickness and vascularity for the detection of distal bowel inflammation. Findings were correlated with colonoscopy and histological findings. The sensitivity and specificity of sonographic wall thickness to detect inflammation was determined. Spearman's coefficient (rs) was used to determine the correlation of Doppler findings with colonoscopy/histology. RESULTS: Sonograms of 372 bowel segments were evaluated and results were correlated with colonoscopy and histological findings of 352 segments. The sensitivity and specificity of sonographic bowel thickness to detect inflammation in the terminal ileum and the right colon were high; in the other segments, specificity was high but sensitivity was low. The correlation of Doppler sonography with colonoscopy and histology to detect inflammation in the terminal ileum was strong (rs: 0.84; p<0.001) and in the other segments, weak to moderate; when the interval between examinations was shorter than 10 days, the correlation was stronger in all segments. Of nine patients with abnormal small bowel sonograms but normal colonoscopies, three had Crohn's disease. CONCLUSION: Sensitivity and specificity of grey-scale sonography to detect inflammation in the terminal ileum and the right colon were high, and the correlation of Doppler with colonoscopy and histology was very strong in the same segments.</p>
<p>PMID: 18718226 [PubMed - in process]</p> (Source: Clinical Radiology)
Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
A family of biodegradable polymers called polyketals and their derivatives may improve treatment for such inflammatory illnesses as acute lung injury, acute liver failure and inflammatory bowel disease by delivering drugs, proteins and snips of ribonucleic acid to disease locations in the body. (Source: ScienceDaily Headlines)
Risks and clinical features of colorectal cancer complicating crohn's disease in japanese patients
Background and Aim: No reports on the relative risk of development of colorectal cancer (CRC) in Japanese patients with Crohn's disease (CD) have been published. The present study aimed to investigate the relative risk and the clinical features of CRC complicating CD among patients managed at Fukuoka University Chikushi Hospital, Fukuoka, Japan (a tertiary referral center for inflammatory bowel diseases).Methods: The clinical backgrounds were analyzed of 512 patients with CD who have been treated by our department during the last 20-year period (1985[ndash]2005) (total 6212.6 person years at risk). The standardized incidence ratio (SIR) refers to the relative risk of CRC in the subjects as compared with that in a sex- and age-matched healthy population.Results: There were six cases with CRC. The SIR was significantly higher (3.2-fold higher; 95% confidence interval, 1.2[ndash]6.9 P < 0.05) in the CD group than in the healthy population. The significant risk factors identified were female sex, mixed small and large bowel type, observation period over 20 years, onset of CD at less than 25 years of age, presence of anal disease, and positive history of surgery. The prognosis for the six cases with CRC was very poor (five cases died within 1.5 years).Conclusion: The risk of CRC in longstanding CD in Japan was similar to that in Western countries. The necessity of surveillance in the management of CD would also need to be discussed in the near future, especially in CD patients with anal lesions or fistulae, and are particularly important in patients with a 20-year or more history of CD. (Source: Journal of Gastroenterology and Hepatology)
Association of vitamin d receptor gene polymorphisms in iranian patients with inflammatory bowel disease
Background and Aims: The vitamin D receptor (VDR) gene maps to a region on chromosome 12 shown to be linked to inflammatory bowel disease (IBD). Many studies have recognized the relation of VDR gene polymorphisms with inflammatory and autoimmune disorders. Determining the frequency of these polymorphisms and their possible relation with IBD can improve understandings about the genetic background of these diseases. The objective of this study was to assess the association of VDR gene polymorphisms (Apa I, Taq I, Bsm I, Fok I) with IBD in Iran.Methods: In this case control designed study 150 patients with ulcerative colitis, 80 patients with Crohn's disease and 150 Age and Sex matched healthy controls from Iranian origin were enrolled. These patients were referred to a tertiary center during a two-year period (2004[ndash]2006). Assessment of VDR gene polymorphisms was performed by the polymerase chain reaction[mdash]restriction fragment length polymorphism (PCR-RFLP) method. The genotype[ndash]phenotype association for these polymorphisms was analyzed.Results: Only the frequency of the Fok I polymorphism was significantly higher in ulcerative colitis and Crohn's groups. The frequency of the polymorphic allele f was higher in ulcerative colitis and Crohn's patients comparing with controls (P = 0.011 and P < 0.001, respectively). The f/f genotype was also significantly more frequent (P < 0.001), while the F/F genotype was less presented in Crohn's patients compared to controls (P < 0.001). No genotype[ndash]phenotype association was observed with any mutations.Conclusions: This study suggests a probable association of the Fok I polymorphism in VDR receptor gene and Crohn's susceptibility in Iranian population. (Source: Journal of Gastroenterology and Hepatology) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Deletion polymorphism upstream of irgm associated with altered irgm expression and crohn's disease
Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease
Nature Genetics 40, 1107 (2008). doi:10.1038/ng.215
Authors: Steven A McCarroll, Alan Huett, Petric Kuballa, Shannon D Chilewski, Aimee Landry, Philippe Goyette, Michael C Zody, Jennifer L Hall, Steven R Brant, Judy H Cho, Richard H Duerr, Mark S Silverberg, Kent D Taylor, John D Rioux, David Altshuler, Mark J Daly
& Ramnik J Xavier
Following recent success in genome-wide association studies, a critical focus of human genetics is to understand how genetic variation at implicated loci influences cellular and disease processes. Crohn's disease (CD) is associated with SNPs around IRGM, but coding-sequence variation has been excluded as a source of this association. We identified a common, 20-kb deletion polymorphism, immediately upstream of IRGM and in perfect linkage disequilibrium (r2 = 1.0) with the most strongly CD-associated SNP, that causes IRGM to segregate in the population with two distinct upstream sequences. The deletion (CD risk) and reference (CD protective) haplotypes of IRGM showed distinct expression patterns. Manipulation of IRGM expression levels modulated cellular autophagy of internalized bacteria, a process implicated in CD. These results suggest that the CD association at IRGM arises from an alteration in IRGM regulation that affects the efficacy of autophagy and identify a common deletion polymorphism as a likely causal variant. (Source: Nature Genetics)
An snp-guided microrna map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.
<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Display&dopt=PubMed_PubMed&from_uid=18719369">Related Articles</a></td></tr></table>
<p><b>An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.</b></p>
<p>Cell Cycle. 2008 Aug 30;7(16)</p>
<p>Authors: Glinsky GV</p>
<p>Recent large-scale genome-wide association (GWA) studies of SNP variations captured many thousands individual genetic profiles of H. sapiens and facilitated identification of significant genetic traits which are highly likely to influence the pathogenesis of several major human diseases. Here we apply the integrative genomics principles to interrogate relationships between structural features and gene expression patterns of disease-linked SNPs, microRNAs and mRNAs of protein-coding genes in association to phenotypes of 15 major human disorders, namely bipolar disease (BD); rheumatoid arthritis (RA); coronary artery disease (CAD); Crohn's disease (CD); type 1 diabetes (T1D); type 2 diabetes (T2D); hypertension (HT); ankylosing spondylitis (AS); Graves' disease (autoimmune thyroid disease; AITD); multiple sclerosis (MS); breast cancer (BC); prostate cancer (PC); systemic lupus erythematosus (SLE); vitiligo-associated multiple autoimmune disease (VIT); and ulcerative colitis (UC). We selected for sequence homology profiling a set of approximately 250 SNPs which were unequivocally associated with common human disorders based on multiple independent studies of 220,124 individual samples comprising 85,077 disease cases and 129,506 controls. Our analysis reveals a systematic primary sequence homology/complementarity-driven pattern of associations between disease-linked SNPs, microRNAs and protein-coding mRNAs defined here as a human disease phenocode. We utilize this approach to draw SNP-guided microRNA maps of major human diseases and define a consensus disease phenocode for fifteen major human disorders. A consensus disease phenocode comprises 72 SNPs and 18 microRNAs with an apparent propensity to target mRNA sequences derived from a single protein-coding gene, KPNA1. Each of microRNAs in this elite set appears linked to at least three common human diseases and has potential protein-coding mRNA targets among the principal components of the nuclear import pathway. We confirmed the validity of our findings by analyzing independent sets of most significant disease-linked SNPs and demonstrating statistically significant KPNA1-gene expression phenotypes associated with human genotypes of CD, BD, T2D and RA populations. Our analysis supports the idea that variations in DNA sequences associated with multiple human diseases may affect phenotypes in trans via non-protein-coding RNA intermediaries interfering with functions of microRNAs and defines the nuclear import pathway as a potential major target in 15 common human disorders.</p>
<p>PMID: 18719369 [PubMed - as supplied by publisher]</p> (Source: Cell Cycle)
Azathioprine is effective for the treatment of both crohn's disease (cd) and ulcerative colitis.
Page: 20 (Source: Inpharma Weekly)
Clinical and immunologic features of pediatric patients with common variable immunodeficiency and respiratory complications.
<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Display&dopt=PubMed_PubMed&from_uid=18714533">Related Articles</a></td></tr></table>
<p><b>Clinical and immunologic features of pediatric patients with common variable immunodeficiency and respiratory complications.</b></p>
<p>J Investig Allergol Clin Immunol. 2008;18(4):260-5</p>
<p>Authors: Aydogan M, Eifan AO, Gocmen I, Ozdemir C, Bahceciler NN, Barlan IB</p>
<p>BACKGROUND: Common variable immunodeficiency (CVID) is the term used to describe a heterogeneous group of B-cell deficiency syndromes characterized by hypogammaglobulinemia, impaired antibody production, and recurrent bacterial infections. OBJECTIVES: To determine the clinical manifestations and perform an immunological analysis of pediatric CVID patients suffering from respiratory complications. METHODS: The records of 10 patients with CVID who were followed up from 1992 to 2005 (6 males and 4 females) with a median (interquartile range) age of 13.9 (10.4-19.4) years were reviewed. All patients met the standard criteria set for CVID. RESULTS: Median total serum levels of immunoglobulin (Ig) G, IgM, and IgA in mg/dL were 383.5 (239.2-574.5), 32.5 (17.0-117.0), and 12.5 (5.0-30.7), respectively. Median age at the onset of symptoms, at CVID diagnosis, and on starting intravenous Ig therapy was 4.0 (0.8-6.2), 9.4 (6.7-11.3), and 9.1 (7.0-11.6) years, respectively. Associated disorders were recurrent infections (100%), bronchiectasis (90%), and growth failure (80%), whereas malabsorption, malignant neoplasm, inflammatory bowel disease, and autoimmune disorders were less common. All bronchiectatic patients had a low percentage of B cells, with an average of 4% (range, 1%-7%). The characteristic computed tomography finding in patients with CVID was a multilobar pattern. Malignant neoplasm developed an average of 11.5 (range, 6.5-20.2) years after the diagnosis of CVID was made. CONCLUSION: Recurrent respiratory infection should be evaluated to rule out CVID. Early diagnosis and intravenous Ig replacement therapy may reduce the frequency of respiratory infection. Low levels of serum Ig and percentage of B lymphocytes at diagnosis are important parameters for identifying patients at risk of structural lung damage.</p>
<p>PMID: 18714533 [PubMed - in process]</p> (Source: Journal of Investigational Allergology & Clinical Immunology)
Effect of the detoxifying and myogenic herb enema in treating 19 patients with ulcerative colitis
Effect of the detoxifying and myogenic herb enema in treating 19 patients with ulcerative colitis
Content Type Journal ArticleCategory Clinical ExperiencesDOI 10.1007/BF02934698Authors
Chang Gao, The Third Affiliated Hospital of The Third Military Medical University of the PLA 630042 ChongqingPei-Yuan Xie, The Third Affiliated Hospital of The Third Military Medical University of the PLA 630042 ChongqingYu-Guang Dai, The Third Affiliated Hospital of The Third Military Medical University of the PLA 630042 Chongqing
Journal Chinese Journal of Integrative MedicineOnline ISSN 1993-0402Print ISSN 1672-0415
Journal Volume Volume 2
Journal Issue Volume 2, Number 4 / December, 1996 (Source: Chinese Journal of Integrative Medicine) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in crohn's disease: a randomized multicenter trial (lir!c-trial)
Background:
With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction.
The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs.
Methods/design: The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007.DiscussionThe LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab treatment or surgery is the best treatment for recurrent distal ileitis in Crohn's disease.
Trial registration:
Nederlands Trial Register NTR1150 (Source: BMC Surgery)
Students with inflammatory bowel disease 'need more support'
Students with Crohn's disease and ulcerative colitis find it difficult adjusting to university life, say researchers who call for more support for students with inflammatory bowel disease. (Source: MedWire News - Consumer Health)
Depression common in bowel disease patients
People with Crohn's disease and ulcerative colitis are more likely to suffer from depression than those without inflammatory bowel disease, study results show. (Source: MedWire News - Consumer Health)
Bone marrow stem cells may help control inflammatory bowel disease
Investigators have found that infusions of a particular bone marrow stem cell appeared to protect gastrointestinal tissue from autoimmune attack in a mouse model. (Source: ScienceDaily Headlines)
Polyketals may improve treatment of inflammatory diseases
A family of biodegradable polymers called polyketals and their derivatives may improve treatment for such inflammatory illnesses as acute lung injury, acute liver failure and inflammatory bowel disease by delivering drugs, proteins and snips of ribonucleic acid to disease locations in the body. (Source: Health News from Medical News Today) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Infliximab for ulcerative colitis in children and adolescents.
Page: 875DOI: 10.1097/MCG.0b013e3181354417Authors: McGinnis, Jean K. ARNP, MN *; Murray, Karen F. MD + (Source: Journal of Clinical Gastroenterology)
Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease.
Page: 880DOI: 10.1097/MCG.0b013e3181354440Authors: Foster, Erina N. MD *; Quiros, J. Antonio MD +; Prindiville, Thomas P. MD * (Source: Journal of Clinical Gastroenterology)
Prospective evaluation of the relationship between stress and relapse in ulcerative colitis.
Page: 963DOI: 10.1097/MCG.0b013e318178d1baAuthors: Hart, Ailsa L. BMBCh, PhD, MRCP *; Plamondon, Sophie MD, FRCPC *; Emmanuel, Anton V. MD, FRCP * +; Kamm, Michael A. MBBS, MD FRCP, FRACP * (Source: Journal of Clinical Gastroenterology)
Epigenetic regulation of wnt signaling pathway genes in inflammatory bowel disease (ibd) associated neoplasia
Abstract
Introduction WNT signaling pathway dysregulation is an important event in the pathogenesis of colorectal cancer (CRC) with APC mutations seen in more than 80% of sporadic CRC. However, such mutations in the WNT signaling pathway genes are rare in inflammatory
bowel disease (IBD) associated neoplasia (dysplasia and cancer). This study examined the role of epigenetic silencing of WNT
signaling pathway genes in the pathogenesis of IBD-associated neoplasia.
Methods Paraffin-embedded tissue samples were obtained and methylation of ten WNT signaling pathway genes, including APC1A, APC2, SFRP1, SFRP2, SFRP4, SFRP5, DKK1, DKK3, WIF1 and LKB1, was analyzed. Methylation analysis was performed on 41 IBD samples, 27 normal colon samples (NCs), and 24 sporadic CRC samples.
Results Methylation of WNT signaling pathway genes is a frequent and early event in IBD and IBD-associated neoplasia. A progressive
increase in the percentage of methylated genes in the WNT signaling pathway from NCs (4.2%) to IBD colitis (39.7%) to IBD-associated
neoplasia (63.4%) was seen (NCs vs. IBD colitis, p?<?0.01; IBD colitis vs. IBD-associated neoplasia, p?=?0.01). In the univariate logistic regression model, methylation of APC2 (OR 4.7, 95% CI: 1.1?20.63, p?=?0.04), SFRP1 (OR 5.1, 95% CI: 1.1?31.9, p?=?0.04), and SFRP2 (OR 5.1, 95% CI: 1.1?32.3, p?=?0.04) was associated with progression from IBD colitis to IBD-associated neoplasia, while APC1A methylation was borderline significant (OR 4.1, 95% CI: 0.95?17.5, p?=?0.06). In the multivariate logistic regression model, methylation of APC1A and APC2 was more likely to be associated with IBD-associated neoplasia than IBD colitis. (OR APC1A: 6.4, 95% CI: 1.1?37.7 p?=?0.04; OR APC2 9.1, 95% CI: 1.3?61.7, p?=?0.02).
Summary Methylation of the WNT signaling genes is an early event seen in patients with IBD colitis and there is a progressive increase
in methylation of the WNT signaling genes during development of IBD-associated neoplasia. Moreover, methylation of APC1A, APC2, SFRP1, and SFRP2 appears to mark progression from IBD colitis to IBD-associated neoplasia, and these genes may serve as biomarkers for IBD-associated
neoplasia.
Content Type Journal ArticleCategory ssat plenary presentationDOI 10.1007/s11605-008-0633-5Authors
Mashaal Dhir, Johns Hopkins University Department of Surgery Baltimore MD 21231 USAElizabeth A. Montgomery, Johns Hopkins University Department of Pathology Baltimore MD 21231 USASabine C. Glöckner, Johns Hopkins University Department of Surgery Baltimore MD 21231 USAKornel E. Schuebel, Johns Hopkins University Department of Oncology Baltimore MD 21231 USACraig M. Hooker, Johns Hopkins University Department of Oncology Baltimore MD 21231 USAJames G. Herman, Johns Hopkins University Department of Oncology Baltimore MD 21231 USAStephen B. Baylin, Johns Hopkins University Department of Oncology Baltimore MD 21231 USASusan L. Gearhart, Johns Hopkins University Department of Surgery Baltimore MD 21231 USANita Ahuja, Johns Hopkins University Department of Surgery Baltimore MD 21231 USA
Journal Journal of Gastrointestinal SurgeryOnline ISSN 1873-4626Print ISSN 1091-255X (Source: Journal of Gastrointestinal Surgery)
Pulmonary nodules as an extra-intestinal manifestation of inflammatory bowel disease: a case series and review of the literature
Pulmonary Nodules as an Extra-Intestinal Manifestation of Inflammatory Bowel Disease: A Case Series and Review of the Literature
Content Type Journal ArticleCategory Case ReportDOI 10.1007/s10620-008-0442-4Authors
Thanhtam Nguyen, University of Minnesota Department of Internal Medicine Minneapolis MN USAChris Shepela, University of Minnesota Division of Gastroenterology, Department of Medicine 420 Delaware St. SE, MMC 36 Minneapolis MN 55455 USAMrinal Patnaik, University of Minnesota Department of Internal Medicine Minneapolis MN USAJose Jessurun, University of Minnesota Department of Lab Medicine and Pathology Minneapolis MN USA
Journal Digestive Diseases and SciencesOnline ISSN 1573-2568Print ISSN 0163-2116 (Source: Digestive Diseases and Sciences) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for crohn's disease in polish patients
Background:
Numerous papers have addressed the association of mutations and polymorphisms of susceptibility genes with autoimmune inflammatory disorders. We investigated whether polymorphisms that confer susceptibility to Crohn's disease could be classified also as predisposing factors for the development of primary sclerosing cholangitis and primary biliary cirrhosis in Polish patients.
Methods:
The study included 60 patients with CD, 77 patients with PSC, of which 61 exhibited IBD (40 UC, 8 CD, and 13 indeterminate colitis), and 144 patients with PBC. All the patients were screened against Crohn's disease associating genetic polymorphisms.
The polymorphisms were chosen according to previously confirmed evidence for association with Crohn's disease, including Pro268Ser, Arg702Trp, Gly908Arg and 1007fs in NOD2/CARD15, Leu503Phe / -207G>C in SLC22A4/OCTN1 / SLC22A5/OCTN2, Arg30Gln in DLG5, Thr300Ala in ATG16L1, and Arg381Gln, His3Gln and exon-3'UTR in IL23R. Genotyping was carried out using TaqMan SNP genotyping assays.
Results:
We confirmed a strong association between three NOD2/CARD15 gene variants (Pro268Ser, OR=2.52, 95% CI=1.34 - 4.75); (Arg702Trp, OR=6.65, 95% CI=1.99 - 22.17); (1007fs, OR=9.59, 95% CI=3.94 - 23.29), and a weak association between both the protective OCTN1/OCTN2 CC haplotype (OR=0.28, 95% CI=0.08 - 0.94), and a variant of ATG16L1 gene (Thr300Ala, OR=0.468, 95% CI=0.24 - 0.90) with Crohn's disease. In contrast, none of the polymorphisms exhibited association with susceptibility to primary sclerosing cholangitis and primary biliary cirrhosis, including a group of primary sclerosing cholangitis patients with concurrent IBD.
Conclusions:
Although the clinical data indicate non-random co-occurrence of inflammatory bowel disease and primary sclerosing cholangitis, consistently with the previously published studies, no genetic association was found between the genetic variants predisposing to Crohn's disease and hepatobiliary autoimmune disorders. However, since estimation of genetic variant disproportion is limited by sample size, these negative results may also indicate that eventually shared genetic predispositions are too little to be captured by small patient groups. (Source: BioMed Central)
[reviews] crohn's disease: current treatment options
There is no known cure for Crohn’s disease (CD), but a better understanding of the evidence base of both established treatments (such as enteral nutrition, corticosteroids, 5-aminosalicylates and immunosuppressive agents) and emerging treatments (such as the anti-tumour necrosis factor- (anti-TNF-) agents, infliximab and adalimumab) provides opportunities to improve and maintain the quality of life for children with the disease. This article provides an overview of the evidence base of current medical treatments that are used to induce and maintain remission in CD. Exclusive enteral nutrition is recommended as the first line of treatment for the induction of remission in paediatric CD. Corticosteroids are also effective for inducing remission but may be associated with significant adverse events. Patients with chronically active CD may benefit from immunosuppressive agents such as azathioprine and methotrexate. Infliximab is effective for inducing remission in patients who continue to have significant active disease despite the use of conventional treatments. Adalimumab may be indicated for patients who develop a severe allergic reaction to infliximab or those who initially respond to infliximab but subsequently lose their response. Treatments that have been shown to be effective for the maintenance of remission include azathioprine, methotrexate, infliximab and adalimumab. Recent evidence also suggests that long-term enteral nutritional supplementation with patients taking about half of their daily calorie requirements as enteral nutrition may be an effective strategy for the maintenance of remission in CD. The available evidence does not support the use of corticosteroids or 5-aminosalicylates as maintenance therapy for CD. (Source: Archives of Disease in Childhood)
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study
BACKGROUND AND AIM: Nearly 25% of patients with ulcerative colitis (UC) requiring steroids therapy become steroid-dependent after 1 yr, and virtually all develop steroid-related adverse events. We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P) encapsulated into erythrocytes (DEE). MATERIALS AND METHODS: Forty patients with mild-to-moderate UC, refractory to mesalamine, were randomly assigned to one of the following three treatments: two DEE infusions 14 days apart (group A, N = 20), oral prednisolone (0.5 mg/kg for 14 days followed by a 6 mg/weekly tapering (group B, N = 10), and sham infusions (group C, N = 10). The clinical, biochemical, and endoscopic parameters were monitored at inclusion and after 8 wk. RESULTS: In group A, a mean dose of 9.9 ± 4.1 mg Dex 21-P was loaded into autologous erythrocytes at each infusion. At 8 wk, 15 patients in group A (75%), 8 in group B (80%), and 1 in group C (10%, P < 0.001 vs A and B) were in clinical and endoscopic remission. When compared with the baseline values, C-reactive protein (CRP) dropped in groups A (1.6 mg/dL vs 0.4 mg/dL, P= 0.006) and B (1.0 vs 0.5, P= 0.02), but not in group C. No steroid-related adverse events were apparent in the patient treated with DEE, compared with 8 out of 10 patients on oral steroids (P[le] 0.01). CONCLUSION: Low doses of Dex (mean total dose ± 20 mg) loaded into autologous erythrocytes were significantly more effective than sham infusions in terms of symptoms relief, endoscopic, and biochemical improvements in UC patients refractory to mesalamine. In addition, in contrast to oral prednisolone (mean total dose ± 1 g), no steroid-related adverse events were induced. (Am J Gastroenterol 2008;103:1[ndash]8) (Source: The American Journal of Gastroenterology)
[leader] disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases
(Source: Gut)
[commentaries] surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right?
(Source: Gut) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
[intestinal inflammation] protease-activated receptor-2 activation: a major actor in intestinal inflammation
Background and aims:
The role of protease-activated receptor-2 (PAR2) during intestinal inflammation is still unclear due to the fact that PAR2-activating peptide has both pro- and anti-inflammatory properties. The aim of this study was to investigate the effects of PAR2 deficiency (using PAR2-deficient mice, PAR2–/–) in models of colitis, in order to elucidate the role of endogenous PAR2 in the process of inflammation in the gut.
Methods:
Colonic inflammation in wild-type and PAR2–/– mice was induced by dextran sodium sulfate, trinitrobenzene sulfonic acid (TNBS), a T helper-1 predominant model, or oxazolone, a T helper-2 predominant model. Leukocyte recruitment, assessed by intravital microscopy, and inflammatory parameters (myeloperoxidase (MPO), macroscopic and microscopic damage) were assessed during the development of colitis. Lastly, the protein levels of cyclooxygenases (COXs) and adhesion molecules (ICAM-1, VCAM-1, alpha-M, alpha-4) were assessed by using western blot analysis.
Results:
In all three models of colitis, MPO activity, macroscopic damage score and bowel thickness were significantly lower in PAR2–/– mice. Changes in vessel leukocyte recruitment parameters (rolling and adhesion) were also significantly reduced in PAR2–/– mice compared to wild-type mice after the induction of colitis. The protein expression of ICAM-1, VCAM-1 and alpha-4 was significantly attenuated, whereas the expression of COX-1 was significantly increased in PAR2–/– mice challenged with TNBS-induced colitis.
Conclusions:
The role of endogenous PAR2 in the gut is pro-inflammatory and independent of the T helper-1 or -2 cytokine profile. Endogenous PAR2 activation controls leukocyte recruitment in the colon and thus appears as a new potential therapeutic target for the treatment of inflammatory bowel disease. (Source: Gut)
[colorectal cancer] high frequency of early colorectal cancer in inflammatory bowel disease
Background and aim:
To detect precancerous dysplasia or asymptomatic cancer, patients suffering from inflammatory bowel disease often undergo colonoscopic surveillance based on American or British guidelines. It is recommended that surveillance is initiated after 8–10 years of extensive colitis, or after 15–20 years for left-sided disease. These starting points, however, are not based on solid scientific evidence. Our aim was to assess the time interval between onset of inflammatory bowel disease (IBD) and colorectal carcinoma (CRC), and subsequently evaluate how many patients developed cancer before their surveillance was recommended to commence.
Methods:
A nationwide automated pathology database (PALGA) was consulted to identify patients with IBD-associated colorectal carcinoma in seven university medical centres in The Netherlands between January 1990 and June 2006. Data were collected retrospectively from patient charts. Time intervals between onset of disease and cancer diagnosis were calculated in months.
Results:
149 patients were identified with confirmed diagnoses of IBD and CRC (ulcerative colitis n = 89/Crohn’s disease n = 59/indeterminate colitis n = 1). Taking date of diagnosis as the entry point, 22% of patients developed cancer before the 8 or 15 year starting points of surveillance, and 28% if surveillance was commenced 10 or 20 years after diagnosis for extensive or left-sided disease, respectively. Using onset of symptoms to calculate the time interval, 17–22% of patients would present with cancer prior to the surveillance starting points.
Conclusions:
These results show that the diagnosis of colorectal cancer is delayed or missed in a substantial number of patients (17–28%) when conducting surveillance strictly according to formal guidelines. (Source: Gut)
[case reports] use of sirolimus (rapamycin) to treat refractory crohn's disease
We present the case of a 37-year-old woman with severe refractory colonic and perianal Crohn’s disease who had lost response to second-line, steroid-sparing treatments azathioprine, methotrexate and infliximab. For many such patients extensive surgery has often been considered the only option. New insights provided by the results of genome-wide association scanning in Crohn’s disease highlight autophagy, a cellular process implicated in the clearance of intracellular bacteria, as a key process in Crohn’s disease pathogeneses. Sirolimus (rapamycin) is a drug used to upregulate autophagy in cell culture in the laboratory, and in clinical practice to prevent rejection following organ transplantation due to independent immunosuppressive action. Our patient was treated with sirolimus for 6 months at a dose that maintained serum trough levels of 5 ng/ml. There was marked and sustained improvement in Crohn’s disease symptoms with the Harvey–Bradshaw index falling from 13 to 3, in serum markers of inflammation (C-reactive protein fell from 79 to 2) and endoscopic appearance. This is the first reported case of the use of sirolimus to treat Crohn’s disease. (Source: Gut)
[postscript] crohn's-like enterocolitis associated with mycophenolic acid treatment
(Source: Gut)
[postscript] genetic variants in the autophagy pathway contribute to paediatric crohn's disease
(Source: Gut) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Magi2 genetic variation and inflammatory bowel disease
Background: Despite recent advances the majority of inflammatory bowel disease (IBD) susceptibility 'genes' remain undiscovered. Recent data suggest that autoimmune conditions may 'share' susceptibility loci. Epidemiological evidence indicates an association between celiac disease and IBD and both conditions demonstrate increased gut permeability. MAGI2, recently implicated in ulcerative colitis (UC) and celiac disease, encodes a scaffolding protein involved in epithelial integrity. Our aim was to test MAGI2 variants for association with IBD and also their role in determining intermediate hereditary phenotypes defined by antibody production to microbial antigens.Methods: We genotyped 113 MAGI2 single nucleotide polymorphisms (SNPs) in 681 cases of Crohn's disease (CD), 259 UC cases, and 195 controls.Results: The most significant IBD association was in intron 6 (rs2160322, P = 0.009) and both UC (P = 0.006) and CD (P = 0.03) contributed to this association. The most significant CD association was with an intron 2 haplotype (rs7785088/rs323149/rs13246026, P = 0.002). We observed highly significant associations with UC in intron 6 (rs7803276/rs7803705, P = 0.002) and also significant associations in introns 2, 6, and 20. Significant associations were seen with: immunoglobulin G (IgG) anti-Saccharomyces cerevisiae antibodies (ASCA)-positive CD in intron 3 (P = 0.003), intron 6 (P = 0.003), and intron 20 (P = 0.001); anti-CBir1-positive CD in intron 3 (P = 0.0001) and intron 6 (P = 0.008); and anti-outer membrane porin C (OmpC)-positive CD in intron 3 (P = 0.0009), and intron 9 (P = 0.007). Quantitative antibody levels were also associated with variants in intron 4 (anti-IgA ASCA, P = 0.0003 and anti-IgG ASCA, P = 0.0002).Conclusions: These findings support the significance of the epithelial barrier in IBD pathogenesis.(Inflamm Bowel Dis 2008) (Source: Inflammatory Bowel Diseases)
Comprehensive disease control: can we differentiate among the biologic agents in crohn's disease? (slides with transcript)
(Source: Medscape FamilyMedicine Headlines)
Welcome and introduction: setting new treatment goals for crohn's disease in 2008 (slides with transcript)
(Source: Medscape FamilyMedicine Headlines)
Comprehensive disease control: can we differentiate among the biologic agents in crohn's disease? (slides with audio)
(Source: Medscape FamilyMedicine Headlines)
Welcome and introduction: setting new treatment goals for crohn's disease in 2008 (slides with audio)
(Source: Medscape FamilyMedicine Headlines) <p> </p><p><b><i>MedWorm Sponsored Message:</i></b> Find out how you can <a href="http://www.medworm.com/rss/medicalsponsorship.php" target="_self">get your message across here</a> by sponsoring this MedWorm news feed.</p>
Differentiating among biologic agents in crohn's disease: applying clinical data to daily treatment decisions
Review the similarities and differences between biologic agents, as well as their optimal use, in the treatment of Crohn's disease. (Source: Medscape FamilyMedicine Headlines)
Inflammatory bowel disease following solid organ transplantation.
<table border="0" width="100%"><tr><td align="left"/><td align="right"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Display&dopt=PubMed_PubMed&from_uid=18708022">Related Articles</a></td></tr></table>
<p><b>Inflammatory bowel disease following solid organ transplantation.</b></p>
<p>Clin Immunol. 2008 Sep;128(3):287-93</p>
<p>Authors: Hampton DD, Poleski MH, Onken JE</p>
<p>Inflammatory bowel disease (IBD) is a T cell driven inflammatory condition of the gut. Following solid organ transplantation (SOT), de novo IBD has been reported despite anti-T cell therapy for the prevention of organ rejection. This paradox is illustrated with a case report, highlighting the difficult diagnostic criteria, the potential role of Damage or Pathogen Associated Molecular Pattern Molecules [DAMPs and PAMPs] that drives aspects of ongoing inflammation within the transplanted organ as well as the intestine, and the therapeutic strategies applied. Recurrent IBD is more common than de novo IBD following transplantation, with cumulative risks ten years after orthotopic liver transplantation of 70% and 30%, respectively. Furthermore, the annual incidence of de novo IBD following solid organ transplantation has been estimated to be 206 cases/100,000 or ten times the expected incidence of IBD in the general population (approximately 20 cases/100,000). The association of IBD with other autoimmune conditions such as primary sclerosing cholangitis and autoimmune hepatitis, both common indications for liver transplantation, may play a contributory role, particularly in view of the observation that IBD is more common following liver transplant than other solid organ transplants. Recurrent IBD following transplant appears to run a more aggressive course than de novo IBD, with a higher proportion requiring colectomy for medically refractory disease. Risk factors that have been associated with development of post-transplant IBD include acute CMV infection and the use of tacrolimus.</p>
<p>PMID: 18708022 [PubMed - in process]</p> (Source: Clinical Immunology)
Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
(Georgia Institute of Technology Research News) A family of biodegradable polymers called polyketals and their derivatives may improve treatment for such inflammatory illnesses as acute lung injury, acute liver failure and inflammatory bowel disease by delivering drugs, proteins and snips of ribonucleic acid to disease locations in the body. (Source: EurekAlert! - Biology)
Bone marrow stem cells may help control inflammatory bowel disease
(Massachusetts General Hospital) Massachusetts General Hospital investigators have found that infusions of a particular bone marrow stem cell appeared to protect gastrointestinal tissue from autoimmune attack in a mouse model. (Source: EurekAlert! - Medicine and Health)
|
|
